品名：Seraseq® FFPE Lymphoma DNA Reference Material

货号：0710-2202 

品牌：SeraCare 

Product Specifications - Lymphoma DNA Mutation Mix   

# of variants：26 

# of vials/kit：1 

Fill Volume：10 µm 

Concentration：1 FFPE curl/vial 

Total Mass：>100 ng*

Format：FFPE 

*QIAamp DNA FFPE Tissue Kit & Qubit ds DNA HS assay 

Details

INTRODUCTION 

To help clinical labs performing NGS-based lymphoid testing better develop, characterize, validate and routinely 

assess lymphoid diseases by NGS assays, LGC SeraCare has developed the Seraseq Lymphoma DNA Mutation 

Mix and Seraseq FFPE Lymphoma Reference Material, the first set of comprehensive lymphoid cancer NGS assay

 reference materials. These unique products include clinically important SNVs, INDELs and gene fusions important 

in lymphoma disease diagnosis and prognosis. Variants are present against a single well-characterized genomic 

background (GM24385) at clinically relevant allele frequencies, precisely quantitated by digital PCR assays. 

FEATURES AND BENEFITS 

Develop and validate Lymphoid-based NGS assays with confidence using a highly multiplexed reference material 

containing biomarkers important in Lymphoma cancers. 

Provide robust sensitivity to detect clinically-relevant mutations at variant allele frequencies that establish and 

validate assay LoD claims. 

Mutation targets are quantitated using highly sensitive digital PCR as well as a custom NGS assay. 

All mutations are blended against GM24385 human genomic DNA as background ‘wild-type’ material. 

Available as both purified DNA mix and FFPE curls, for end-to-end assay workflow positive control. 

Manufactured in GMP-compliant and ISO 13485-certified facilities. 

维百奥生物代理SeraCare对照及参比物质。

维百奥（北京）生物科技有限公司，自2018年与SeraCare（现隶属于LGC Clinical Diagnostics）合作以来，长期为中国客户

提供包括SeraSeq系列参比物质，领域包括肿瘤、生殖健康和遗传病。SeraCare研发和生产一系列临床参比物质，可以用于任何

研发阶段，以确保临床基因组学检测结果的准确性。

SeraCare参比物质涵盖的范围：

1）Next Generation Sequencing

2）Sanger Sequencing

3）Real-time PCR and digital PCR (dPCR)

4）Microarray

主要特点

1）Ready-to-use reference materials covering clinically-relevant variants and all variant types - SNVs, INDELS, CNVs, 

and RNA fusions

2）Highly multiplexed - provide significantly more data per NGS run, saving sequencing costs

3）Available in multiple formats to suite different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA 

in plasma, and FFPE

4）Manufactured in cGMP-compliant, ISO 13485-certified facilities

5）Stringent product release testing - all variants qualified by dPCR for allele frequencies or copy numbers